Cosmo Bio Co

Cosmo Bio Co Operating Cash Flow

The Operating Cash Flow of Cosmo Bio Co (3386.T) as of Nov 2, 2026 is 595.00 M JPY. In the previous year, Operating Cash Flow was 241.00 M JPY — a change of 146.89% (higher).

Operating Cash Flow

595.00 MJPY

YoY

146.89%

Last updated:

Operating Cash Flow of Cosmo Bio Co is 2025 595.00 M JPY. Operating Cash Flow of Cosmo Bio Co was 2024 241.00 M JPY. It decreases by 146.89% higher compared to the previous year.

The Cosmo Bio Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
908.00 M JPY
Jan 1, 2019
569.00 M JPY
Jan 1, 2020
803.00 M JPY
Jan 1, 2021
648.00 M JPY
Jan 1, 2022
284.00 M JPY
Jan 1, 2023
736.00 M JPY
Jan 1, 2024
241.00 M JPY
Jan 1, 2025
595.00 M JPY
The Cosmo Bio Co Operating Cash Flow history
YEAROperating Cash FlowYoY
595.00 MJPY+146.89%
241.00 MJPY-67.26%
736.00 MJPY+159.15%
284.00 MJPY-56.17%
648.00 MJPY-19.30%
803.00 MJPY+41.12%
569.00 MJPY-37.33%
908.00 MJPY+920.22%
89.00 MJPY-84.44%
572.00 MJPY+343.41%
129.00 MJPY-56.57%
297.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Operating Cash Flow of Cosmo Bio Co is 595.00 M JPY in 2025.

Operating Cash Flow of Cosmo Bio Co changed from 241.00 M JPY to 595.00 M JPY, representing a 146.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co